Elizabeth S Grimm

US Patent:

6797702, Sep 28, 2004

Filed:

Aug 26, 1997

Appl. No.:

08/918407

Inventors:

Jack A. Roth - Houston TX
Toshiyoshi Fujiwara - Okayama, JP
Elizabeth A. Grimm - Houston TX
Tapas Mukhopadhyay - Houston TX
Wei-Wei Zhang - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 31713

US Classification:

514 44, 4353201, 536 231, 536 241

Abstract:

The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.

US Patent:

7109179, Sep 19, 2006

Filed:

Feb 23, 2004

Appl. No.:

10/784538

Inventors:

Jack A. Roth - Houston TX, US
Toshiyoshi Fujiwara - Okayama, JP
Elizabeth A. Grimm - Houston TX, US
Tapas Mukhopadhyay - Houston TX, US
Wei-Wei Zhang - Houston TX, US

Assignee:

Board of Regents, the University of Texas System - Austin TX

International Classification:

A61K 31/713

US Classification:

514 44, 4353201, 536 231, 536 241

Abstract:

The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.

US Patent:

20020183271, Dec 5, 2002

Filed:

Dec 7, 2001

Appl. No.:

10/017472

Inventors:

Sunil Chada - Missouri City TX, US
Elizabeth Grimm - Houston TX, US
Abner Mhashilkar - Houston TX, US
Rajagopal Ramesh - Sugarland TX, US

International Classification:

A61K048/00
A61K038/43

US Classification:

514/044000, 424/094100

Abstract:

The present invention relates to gene therapy methods for the treatment of human disease. More specifically, the invention is directed to methods for treating a subject with an angiogenesis-related disease. In one embodiment, an adenoviral expression construct comprising a nucleic acid encoding a human MDA-7 protein under the control of a promoter operable in eukaryotic cells, is administered to said patient with an angiogenesis-related disease. The present invention thus provides for treatment of angiogenesis-related disease by through expression of mda-7 and inhibition angiogenesis. Such diseases include cancer.

US Patent:

20060134801, Jun 22, 2006

Filed:

Mar 2, 2004

Appl. No.:

10/791692

Inventors:

Sunil Chada - Missouri City TX, US
John Mumm - Sugar Land TX, US
Rajagopal Ramesh - Sugar Land TX, US
Abner Mhashilkar - Birmingham AL, US
Raymond Meyn - Houston TX, US
Elizabeth Grimm - Houston TX, US

International Classification:

G01N 1/10

US Classification:

436177000

Abstract:

The present invention relates to compositions and methods involving MDA-7. More specifically, the present invention is directed to diagnostic, prognostic, and therapeutic treatment compositions and methods for treatment of cancer and other angiogenesis-related disorders (anti-angiogenesis therapy). The present invention is also directed to methods of purification of MDA-7.

US Patent:

20060182718, Aug 17, 2006

Filed:

Feb 6, 2006

Appl. No.:

11/348506

Inventors:

Jack Roth - Houston TX, US
Toshiyoshi Fujiwara - Okayoma, JP
Elizabeth Grimm - Houston TX, US
Tapas Mukhopadhyay - Houston TX, US
Wei-Wei Zhang - Houston TX, US

International Classification:

A61K 48/00
A61K 31/7072
A61K 31/7048
A61K 31/704
A61K 31/513
A61K 31/4745
A61N 5/00
A61K 33/24

US Classification:

424093200, 424649000, 514034000, 514027000, 514283000, 514049000, 514269000, 600001000

Abstract:

The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.

US Patent:

52291090, Jul 20, 1993

Filed:

Apr 14, 1992

Appl. No.:

7/868765

Inventors:

Elizabeth A. Grimm - Houston TX
Keith Heaton - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 4505

US Classification:

424 852

Abstract:

The properties of two recombinant human IL-2 analogues with mutations at Arginine 38 (. fwdarw. Alanine) and Phenylalanine 42 (. fwdarw. Lysine) were analyzed and compared to those of native IL-2. These analogues were found to maintain their ability to bind to the intermediate IL-2 receptor, p75, while binding only minimally to the high affinity p55+p75 receptor complex. The analogues also maintained the ability to stimulate peripheral blood mononuclear cells to generate lymphokine activated killing (LAK). However, IL-1. beta. and TNF-. alpha. secretion were significantly reduced in response to the analogues, as compared to the native IL-2 molecule. These analogues are therefore potentially valuable low-toxicity alternatives to IL-2 in human immunotherapy and adoptive immunotherapy treatment strategies.

US Patent:

60691344, May 30, 2000

Filed:

Oct 17, 1997

Appl. No.:

8/953290

Inventors:

Jack A. Roth - Houston TX
Toshiyoshi Fujiwara - Okayama, JP
Elizabeth A. Grimm - Houston TX
Tapas Mukhopadhyay - Houston TX
Wei-Wei Zhang - Houston TX

Assignee:

Board of Regents, The University of Texas System

International Classification:

A61K 4800

US Classification:

514 44

Abstract:

The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.

US Patent:

57474699, May 5, 1998

Filed:

Apr 25, 1994

Appl. No.:

8/233002

Inventors:

Jack A. Roth - Houston TX
Toshiyoshi Fujiwara - Okayama, JP
Elizabeth A. Grimm - Houston TX
Tapas Mukhopadhyay - Houston TX
Wei-Wei Zhang - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 4800
C12N 500
C12N 1500

US Classification:

514 44

Abstract:

The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.

Address:

6516 Brompton Rd, Houston, TX 77005

Phone:

(713)6656059

VIN:

WDBTJ56H07F222144

Make:

MERCEDES-BENZ

Model:

CLK-CLASS

Year:

2007